Novo's €2.6bn Ablynx Bid Opens The Door For Better Offers

Gilead, Amgen and AbbVie are names that could join the fray should a bidding war start for Nanobody drug developer Ablynx, which has rebuffed two takeover offers from Novo Nordisk.

Auction
Could rival bidders bring in better offers to acquire Ablynx? • Source: Shutterstock

Novo Nordisk AS wants to acquire Belgian Nanobody developer Ablynx NV for €2.6bn to access its late-stage blood disorder drug caplacizumab, but Ablynx has rejected two offers from the diabetes giant because the figures "fundamentally undervalue Ablynx and its strong prospects for continued growth."

While a takeover would make sense for Novo Nordisk, which desperately needs to boost its pipeline outside of diabetes and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.